JPRN-UMIN000003215招募中2 期
A Phase II Study for the efficacy and safety of Erlotinib for Patients previously treated Non-small cell Lung Cancer Patients with EGFR Mutations - A Phase II Study for the efficacy and safety of Erlotinib for Patients previously treated Non-small cell Lung Cancer Patients with EGFR Mutations
Fujita Health Universty Hospital Division of Respirology and Allergology0 个研究点目标入组 28 人开始时间: 2010年2月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Active infection (fever) 2)Cases with past history of EGFR-TKI 3)Presence of active interstitial lung disease or pulmonary fibrosis 4)Patients with massive pleural or prericardial effusion or ascites 5)Patients with uncontrollable complications 6)Patients with active double cancer 7)Pregnancy or lactation. 8)Patients whose participation in the trial is judged to be inappropriate by the attending doctor.
研究者
相似试验
招募中
2 期
A study to test an oral combination of letrozole and everolimus for patients with advanced lung cancer who have progressed on first line chemotherapy.on Small Cell lung cancerNon Small Cell lung cancerCancer - Lung - Non small cellACTRN12607000218493Dept of Medical Oncology, Royal Adelaide Hospital20
已完成
1 期
Evaluation of efficacy and safety of Ebola vaccine iEvac-Z in humaJPRN-jRCTs031190118Koga Michiko30
尚未招募
2 期
Ayurvedic treatment for pain, swelling and stiffness in all jointsCTRI/2021/03/031630Shree jagadguru gavisidheswara ayurvedic medical college postgraduate studies and research center
尚未招募
2 期
A phase 2 Study of the efficay and safty of erlotinib therapy for 3/4 stage EGFR gene mutation positive EGFR-TKI untreated non-small cell lung cancerJPRN-UMIN000011986Itabashi central medical center21
已完成
1 期
Phase I/II study on the safety and efficacy of repeated administration of FIT039 transdermal patch for verrucas caused by human papilloma-virusPhase I/II study on the safety and therapeutic efficacy of repeated administration of FIT039 transdermal patch on verrucas caused by human papillomavirusJPRN-UMIN000029695Department of Dermatology, Kyoto University Hospital44